FDA Determines Regulatory Review Period for XIAFLEX Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for XIAFLEX, a human biological product, in response to a patent extension application submitted to the Director of Patents and Trademarks at the US Department of Commerce.